Effect of supplementation in treatment of polycystic ovary syndrome

Phase 3

Conditions: Polycystic ovary syndrome.
Polycystic ovarian syndrome
E28.2

Registration Number: IRCT201412295623N33

Lead Sponsor: Ardabil University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: Female

Target Recruitment: 64

Inclusion Criteria

Women aged 18-40 years
Diagnosed with PCOS

Exclusion Criteria

Elevated levels of prolactin
Thyroid disorder
T2DM
Congenital adrenal hyperplasia
Had normal baseline renal function tests, bilirubin, and aminotransferases
During the last 3 months before the intervention used anyform of oral contraceptives (OCPs), steroid hormones, or any other treatments likely to affect ovarian function, insulin sensitivity, or inflammatory factors, biomarkers of oxidative stress.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

Secondary Outcome Measures

Name	Time	Method
Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Free testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.